CONTEXT SENSITIVE DYNAMIC AUTHENTICATION IN A CRYPTOGRAPHIC SYSTEM

• US 20080034209A1
• Filed: 08/16/2007
• Published: 02/07/2008
• Est. Priority Date: 09/20/1999
• Status: Active Grant

• Current Assignee: Security First Innovations, LLC
• Original Assignee: Alexander Dickinson, Brian Berger, Robert Dobson
• Inventors: Dobson, Robert, Dickinson, Alexander, Berger, Brian
• Granted Patent: US 7,802,104 B2
• Time in Patent Office: Days
• US Class Current: 713/168
• CPC Class Codes: G06Q 20/4014 Identity check for transactions
• CPC Class Codes: G06Q 20/4016 involving fraud or risk level assessment in transaction processing
• CPC Class Codes: H04L 2209/56 Financial cryptography, e.g. electronic payment or e-cash
• CPC Class Codes: H04L 2209/805 Lightweight hardware, e.g. radio-frequency identification [RFID] or sensor
• CPC Class Codes: H04L 2463/082 applying multi-factor authentication cryptographic mechanisms or cryptographic arrangements including means for verifying the identity or authority of a user of the system or for message authentication H04L9/32
• CPC Class Codes: H04L 63/0428 wherein the data content is protected, e.g. by encrypting or encapsulating the payload
• CPC Class Codes: H04L 63/08 for authentication of entities cryptographic mechanisms or cryptographic arrangements for entity authentication H04L9/32
• CPC Class Codes: H04L 63/10 for controlling access to devices or network resources
• CPC Class Codes: H04L 9/3226 using a predetermined code, e.g. password, passphrase or PIN network architectures or network communication protocols for supporting authentication of entities using passwords in a packet data network H04L63/083
• CPC Class Codes: H04L 9/3297 involving time stamps, e.g. generation of time stamps
• CPC Class Codes: H04W 12/67 Risk-dependent, e.g. selecting a security level depending on risk profiles

Abstract

A system for performing authentication of a first user to a second user includes the ability for the first user to submit multiple instances of authentication data which are evaluated and then used to generate an overall level of confidence in the claimed identity of the first user. The individual authentication instances are evaluated based upon: the degree of match between the user provided by the first user during the authentication and the data provided by the first user during his enrollment; the inherent reliability of the authentication technique being used; the circumstances surrounding the generation of the authentication data by the first user; and the circumstances surrounding the generation of the enrollment data by the first user. This confidence level is compared with a required trust level which is based at least in part upon the requirements of the second user, and the authentication result is based upon this comparison.

Claims

1. A method comprising the steps of:

introducing a nucleus derived from a donor blastomere along with one or more molecular components selected from the group consisting of a centrosome protein, a centrosomal component from a sperm centrosome, a mitotic motor protein, into an extrusion-enucleated non-human primate egg from a species of a non-human primate, thus creating a nuclear transfer construct;

culturing said nuclear transfer construct to produce a viable non-human primate embryo;

transferring said non-human primate embryo to the oviducts of a non-human primate female of said species; and

producing a cloned non-human primate.

2. The method of claim 1, wherein said enucleated non-human primate egg is a cumulus-free oocyte.

3. The method of claim 1, wherein said enucleated non-human primate egg is enucleated pre-metaphase II.

4. The method of claim 1, wherein said enucleated non-human primate egg is enucleated just prior to metaphase II arrest.

5. The method of claim 1, wherein said extrusion comprises:

holding a non-human primate egg with a holding micropipette;

partially dissecting the zonal pellucida of said non-human primate egg with a needle by making a slit near the first polar body of said non-human primate egg;

extruding the first polar body and adjacent cytoplasm containing the meiotic spindle, ranging from telophase-I to pro-metaphase-II, by squeezing said needle.

6. The method of claim 5, wherein said holding micropipette has an 110 μ

m inner diameter.

7. The method of claim 5, wherein said needle is a glass needle.

8. The method of claim 1, wherein said enuncleated non-human primate egg is enucleated in Hepes-buffered TALP supplemented with BSA and cytochalasin B.

9. The method of claim 1, wherein said enuncleated non-human primate egg is enucleated in Hepes-buffered TALP supplemented with 0.3% BSA and 7.5 μ

g/ml cytochalasin B.

17. The method of claim 1, wherein said nuclei are transferred into the perivitelline space of said enucleated non-human primate egg.

18. The method of claim 1, wherein said nuclear transfer constructs are equilibrated with mannitol solution.

19. The method of claim 18, wherein said mannitol solution comprises about 0.3 M mannitol solution containing 0.5 mM Hepes, 0.1 mM CaCl₂, and 0.1 mM MgCl₂.

20. The method of claim 18, wherein said nuclear transfer constructs are equilibrated with said mannitol solution for 4 minutes.

21. The method of claim 18, wherein after said equilibration with said mannitol solution, said nuclear transfer constructs are transferred to a chamber containing an electrode overlaid with said mannitol solution.

22. The method of claim 18, wherein after said equilibration with said mannitol solution, said nuclear transfer constructs are transferred to a chamber containing electrodes overlaid with said mannitol solution.

23. The method of claim 22, wherein said chamber contains two electrodes overlaid with said mannitol solution.

24. The method of claim 1, wherein said nucleus and said non-human primate egg are fused with two DC pulses.

25. The method of claim 24, wherein said DC pulses constitute 2.7 kV/cm.

26. The method of claim 24, wherein the duration of said DC pulses is 15 μ

s.

27. The method of claim 1, wherein said nuclear transfer construct is developed in culture media.

28. The method of claim 27, wherein said culture media includes G1, G2, and modified synthetic oviductal fluid (mSOF).

29. The method of claim 27, wherein said nuclear transfer construct is developed in said culture media sequentially.

30. The method of claim 27, wherein said nuclear transfer construct is developed in G1 for 48 hours after nuclear transfer.

31. The method of claim 27, wherein said nuclear transfer construct is developed in G1 media for 48 hours after nuclear transfer and then developed in G2 media for an another 48 hours.

32. The method of claim 27, wherein said nuclear transfer construct is developed in G1 media for 48 hours after nuclear transfer and then developed in G2 media for an another 48 hours and transferred to mSOF around the morula stage until said nuclear transfer construct reaches the blastocyst stage.

33. The method of claim 27, wherein said mSOF media further comprises fructose.

34. The method of claim 1, wherein said nucleus has desired characteristics.

35. The method of claim 34, wherein said desired characteristics are linked to a specific disease or disorder.

36. The method of claim 35, wherein said specific disease or disorder is selected from the group consisting of cardiovascular disease, neurological disease, reproductive disorder, cancer, eye disease, endocrine disorder, pulmonary disease, metabolic disorder, autoimmune disorder, and aging.

40. The method of claim 1, wherein said introducing step further comprises performing meiotic spindle collapse.

41. The method of claim 1, further comprising the step of performing ooplasmic supplementation following said introducing step.

42. The method of claim 41, wherein said ooplamsic supplementation is performed by ooplast electrofusion.

43. The method of claim 41, wherein said ooplasmic supplementation is performed by microinjection.

44. The method of claim 1, wherein said one or more molecular components comprise centrosomal components normally present in sperm centrosomes.

45. The method of claim 1, wherein said one or more molecular components comprise mitotic motor proteins and centrosome proteins.

46. The method of claim 45, wherein said mitotic motor proteins comprise kinesins.

47. The method of claim 46, wherein said kinesins comprise HSET kinesin.

48. The method of claim 45, wherein said centrosome proteins comprise NuMA.

53. The method of claim 1, wherein said viable non-human primate embryo is transgenic.

54. The method of claim 1, further comprising the step of producing embryonic stem cells from said viable embryo.

55. The method of claim 54, wherein said embryonic stem cells are human and said viable embryo is human.

10-16. -16. (canceled)

37-39. -39. (canceled)

49-50. -50. (canceled)

52. (canceled)

56-214. -214. (canceled)